Structure Therapeutics Inc., based in South San Francisco, California, is a pioneering biopharmaceutical company focused on creating innovative oral treatments for chronic diseases lacking sufficient medical solutions. Its flagship product, GSBR-1290, is a groundbreaking oral medication aimed at combating type-2 diabetes and obesity by targeting a specific protein receptor involved in these conditions. Additionally, the company is working on developing new therapies for pulmonary and cardiovascular diseases, including treatments for idiopathic pulmonary fibrosis and pulmonary arterial hypertension, showcasing its commitment to addressing serious health challenges through oral therapeutics.
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
